The accuracy of warfarin dosage based on VKORC1 and CYP2C9 phenotypes in a Chinese population

被引:0
|
作者
Wijaya, Agustinus [1 ]
Bo, Jiang T. [1 ]
Jun, He [2 ]
Ping, Jiang W. [1 ]
Bin, Jiang [1 ]
Jie, Chen H. [2 ]
Wen, Yang B. [1 ]
Zhu, Xu M. [1 ]
Cheng, Qiu Q. [2 ]
机构
[1] Soochow Univ, Affiliated Hosp 1, Dept Cardiovasc Dis, Suzhou, Jiangsu, Peoples R China
[2] Soochow Univ, Affiliated Hosp 1, Dept Haematol, Suzhou, Jiangsu, Peoples R China
关键词
CYP2C9; pharmacogenetic algorithm; VKORC1; warfarin;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The aim of this study is to assess the accuracy of warfarin dosage based on VKORC1 and CYP2C9 genotype in Chinese population. Methods: Blood samples were taken from 37 patients. We compared the warfarin dosage obtained from genotype ( according to www. warfarindosing. org) and treatment dosage with international normalized ratio (INR) value within 2.0-3.0. Results: The majority of Chinese people in our study are VKORC1 homozygous AA (89.2%), rarely VKORC1 heterozygous AG and we cannot find a patient with homozygous GG. For CYP2C9 genotype, most patients have the wildtype variants (CYP2C9*2 CC and CYP2C9*3 AA). The warfarin dosage for patients with VKORC1 AA and CYP2C9*3 AC is lower than for patients with other genotype variants. Conclusion: There is no significant difference between pharmacogenetic algorithm (www. warfarindosing. org) and our treatment dosage. Our conclusion is that the pharmacogenetic algorithm is accurate to predict the warfarin dose.
引用
收藏
页码:108 / 112
页数:5
相关论文
共 50 条
  • [1] Polymorphisms of VKORC1 and CYP2C9 are associated with warfarin sensitivity in Chinese population
    Jia, LiQun
    Wang, Zanxin
    Men, Jianlong
    Cai, Heng
    Wei, Minxin
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2017, 13 : 421 - 425
  • [2] Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin
    Flockhart, David A.
    O'Kane, Dennis
    Williams, Marc S.
    Watson, Michael S.
    Flockhart, David A.
    Gage, Brian
    Gandolfi, Roy
    King, Richard
    Lyon, Elaine
    Nussbaum, Robert
    O'Kane, Dennis
    Schulman, Kevin
    Veenstra, David
    Williams, Marc S.
    Watson, Michael S.
    GENETICS IN MEDICINE, 2008, 10 (02) : 139 - 150
  • [3] Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 -: Rationale and perspectives
    Yin, Tong
    Miyata, Toshiyuki
    THROMBOSIS RESEARCH, 2007, 120 (01) : 1 - 10
  • [4] Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population
    Mitchell, Cathrine
    Gregersen, Nerine
    Krause, Amanda
    PHARMACOGENOMICS, 2011, 12 (07) : 953 - 963
  • [6] The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population
    Taskin, Birce Dilge
    Kula, Serdar
    Ergun, Mehmet Ali
    Altun, Demet
    Olgunturk, Rana
    Tunaoglu, Fatma Sedef
    Oguz, Ayse Deniz
    Gursel, Turkiz
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2016, 16 (10) : 791 - 796
  • [7] Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals
    Maryam H. Alrashid
    Ahmad Al-Serri
    Salem H. Alshemmari
    Philip Koshi
    Suzanne A. Al-Bustan
    Molecular Diagnosis & Therapy, 2016, 20 : 183 - 190
  • [8] Distribution of CYP2C9 and VKORC1 Risk Alleles for Warfarin Sensitivity and Resistance in the Israeli Population
    Efrati, Edna
    Elkin, Hela
    Sprecher, Eli
    Krivoy, Norberto
    CURRENT DRUG SAFETY, 2010, 5 (03) : 190 - 193
  • [9] The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population
    Vear, Susan I.
    Ayers, Gregory D.
    Van Driest, Sara L.
    Sidonio, Robert F.
    Stein, Charles Michael
    Ho, Richard H.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 165 (06) : 832 - 835
  • [10] The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians
    Bedewy, Ahmed M. L.
    Showeta, Salah
    Mostafa, Mostafa Hasan
    Kandil, Lamia Saeed
    INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION, 2018, 34 (02) : 328 - 336